SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist
Howard Sard, Govindaraj Kumaran, Cynthia Morency, Bryan L. Roth, Beth Ann Toth, Ping He, Louis Shuster
Bioorganic & Medicinal Chemistry Letters August 3, 2005 DOI: 10.1016/j.bmcl.2005.06.104 via OpenAlex
Summary
AI-generated from the abstractA structure-activity relationship study of psilocybin and psilocin derivatives found that 1-methylpsilocin acts as a selective agonist at the human 5-HT(2C) receptor. Its phosphate derivative, 1-methylpsilocybin, and 4-fluoro-N,N-dimethyltryptamine each showed efficacy in an animal model of obsessive-compulsive disorder. These findings point to a new avenue for developing novel 5-HT(2C) receptor agonists with potential applications in drug discovery.
Study at a glance
| Characteristics | Structure-activity relationship study Peer reviewed |
|---|---|
| Interventions | 1-methylpsilocybin 4-fluoro-N N-dimethyltryptamine |
| Topics | Psilocybin |
| Keywords | Agonist Pharmacology Hallucinogen Drug discovery |
| Citations | 78 |
| Key finding | 1-methylpsilocin is a selective agonist at the h5-HT(2C) receptor, and both 1-methylpsilocybin and 4-fluoro-N,N-dimethyltryptamine show efficacy in an animal model for obsessive-compulsive disorder. |
Abstract
An SAR study of psilocybin and psilocin derivatives reveals that 1-methylpsilocin is a selective agonist at the h5-HT(2C) receptor. The corresponding phosphate derivative, 1-methylpsilocybin, shows efficacy in an animal model for obsessive-compulsive disorder, as does 4-fluoro-N,N-dimethyltryptamine. These results suggest a new area for development of novel 5-HT(2C) agonists with applications for drug discovery.